Clinical Trial Update: Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition) [Phase 4]

View source ↗

Summary

Phase 4 trial update on secondary prevention of atrial fibrillation evaluating the impact of renin-angiotensin-aldosterone system inhibition; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: University of Pittsburgh | Conditions: Atrial Fibrillation | Phase 4 | Status: TERMINATED